The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
If they don't get the right bio-markers from the UNIVERSAL study and elsewhere, then I suspect they will try to kick the can down the road again. They have to get it right this time and accurate bio-markers to identify the most suitable patients are essential for the P2s to succeed.
Andrewcapp - You know the man is behind the screen name of org? What was revealed in the legal case?
So there are four main characters posting here:
the war hero
poor little orphan boy
the cretin over on azn ... and ...
mrcosts
This is all about waiting for the P2 results now.
I suspect there are arrangements in place with a BP (J&J) for a JV *if* the results are statistically significant and suggest the target market is large enough.
Patience until the start of 2024.
I've levelled up and if the sp spikes, I'm out. There probably will be a spike hence the increased unhinged sockpuppet activity.
There's a major crash on the horizon and I'd prefer to be in cash to invest.